Budesonide/formoterol: A review of its use as maintenance and reliever inhalation therapy in asthma

Drugs

Volumn 67, Issue 16, 2007, Pages 2407-2431

  McCormack, Paul L ^a   Lyseng Williamson, Katherine A ^a  

^a Wolters Kluwer Health   (New Zealand)

Author keywords

Adis Drug Evaluations; Asthma; Budesonide formoterol, general

Indexed keywords

ALLERGEN; BECLOMETASONE DIPROPIONATE; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; CYTOCHROME P450 3A4; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; GLUCOCORTICOID RECEPTOR; ITRACONAZOLE; PLACEBO; RITONAVIR; SALBUTAMOL; TERBUTALINE;

ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ASTHMA; BRONCHITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; COUGHING; DISEASE EXACERBATION; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RETENTION; DRUG TOLERABILITY; DRUG TOLERANCE; DYSPHONIA; FORCED EXPIRATORY VOLUME; HEADACHE; HEART PALPITATION; HOARSENESS; HUMAN; LIVER METABOLISM; MAXIMUM PLASMA CONCENTRATION; METERED DOSE INHALER; MONOTHERAPY; PEAK EXPIRATORY FLOW; PHARYNGITIS; RESPIRATORY TRACT INFECTION; REVIEW; RHINITIS; SINUSITIS; SYMPTOM; TACHYCARDIA; THROAT IRRITATION; THRUSH; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR;

EID: 36049038984     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767160-00007     Document Type: Review

References (57)

1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention [online]. Available from URL: http://www.ginasthma.com [Accessed 2007 Aug 8]
2. British Thoracic Society. British guideline on the management of asthma: a national clinical guideline [online]. Available from URL: http://www.sign.ac. uk/pdf/sign63.pdf [Accessed 2007 Aug 8]
3. National Asthma Education and Prevention Program. Expert panel report 3: guidelines for the diagnosis and management of asthma. Full report 2007 [online]. Available from URL: http://www.nhlbi.nih.gov/guidelines/asthma/ asthgdln.htm [Accessed 2007 Sep 20]
4. Bai TR, Vonk JM, Postma DS, et al. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J 2007 Sep; 30 (3): 452-6
5. van der Molen T, Ostrem A, Stallberg B, et al. International Primary Care Respiratory Group (IPCRG) guidelines: management of asthma. Prim Care Respir J 2006 Feb; 15 (1): 35-47
6. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001 Oct 15; 164 (8): 1392-7
7. Pauwels RA, Löfdahl C-G, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997 Nov 13; 337 (20): 1405-11
8. Barnes PJ. Scientific rationale for using a single inhaler for asthma control. Eur Respir J 2007 Mar; 29 (3): 587-95
9. Pauwels RA, Sears MR, Campbell M, et al. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J 2003 Nov; 22 (5): 787-94
10. 2-agonist single-inhaler combination for both maintenance and rescue therapy: a paradigm shift in asthma management. Treat Respir Med 2006; 5 (6): 385-91
11. Remington TL, DiGiovine B. Long-acting β-agonists: anti-inflammatory properties and synergy with corticosteroids in asthma. Curr Opin Pulm Med 2005 Jan; 11 (1): 74-8
12. Brogden RN, McTavish D. Budesonide: an updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis. Drugs 1992; 44 (3): 375-407
13. Hvizdos KM, Jarvis B. Budesonide inhalation suspension: a review of its use in infants, children and adults with inflammatory respiratory disorders. Drugs 2000 Nov; 60 (5): 1141-78
14. Braga PC, Culici M, Dal Sasso M. Budesonide reduces superoxide and peroxynitrite chemiluminescence during human neutrophil bursts [abstract no. 268]. Eur Respir J 2004 Sep; 24 Suppl. 48: 21s
15. Symbicort® (budesonide/formoterol) 200/6 Turbohaler® inhalation powder: summary of product characteristics (UK) [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2007 Jul 24]
16. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000 Oct 12; 343 (15): 1054-63
17. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000 Oct 12; 343 (15): 1064-9
18. Faulds D, Hollingshead LM, Goa KL. Formoterol: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 1991 Jul; 42 (1): 115-37
19. 2-agonists in the management of asthma exacerbations. Curr Opin Pulm Med 2005 Jan; 11 (1): 69-73
20. Goldsmith DR, Keating GM. Budesonide/formoterol: a review of its use in asthma. Drugs 2004; 64 (14): 1597-618
21. Cheer SM, Scott LJ. Formoterol: a review of its use in chronic obstructive pulmonary disease. Am J Respir Med 2002; 1 (4): 285-300
22. Overbeek SE, Mulder PG, Baelemans SM, et al. Formoterol added to low-dose budesonide has no additional antiinflammatory effect in asthmatic patients. Chest 2005 Sep; 128 (3): 1121-7
23. Haahtela T, Tamminen K, Malmberg LP, et al. Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: a SOMA study. Eur Respir J 2006 Oct; 28 (4): 748-55
24. O'Connor TM, Kelly MM, Leigh R, et al. Additional anti-inflammatory effects of inhaled budesonide/formoterol over inhaled budesonide in subjects with atopic asthma [abstract no. P2570]. Eur Respir J 2006 Sep; 28 Suppl. 50: 441s
25. Korn SH, Jerre A, Brattsand R. Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells. Eur Respir J 2001 Jun; 17 (6): 1070-7
26. Duong M, Gauvreau G, Watson R, et al. The effects of inhaled budesonide and formoterol in combination and alone when given directly after allergen challenge. J Allergy Clin Immunol 2007 Feb; 119 (2): 322-7
27. Wilson SJ, Wallin A, Della-Cioppa G, et al. Effects of budesonide and formoterol on NF-κB, adhesion molecules, and cytokines in asthma. Am J Respir Crit Care Med 2001 Sep 15; 164 (6): 1047-52
28. Wallin A, Sandstrom T, Cioppa GD, et al. The effects of regular inhaled formoterol and budesonide on preformed Th-2 cytokines in mild asthmatics. Respir Med 2002 Dec; 96 (12): 1021-5
29. Maneechotesuwan K, Essilfie-Quaye S, Meah S, et al. Formoterol attenuates neutrophilic airway inflammation in asthma. Chest 2005 Oct 1; 128 (4): 1936-42
30. Capraz F, Kunter E, Cermik H, et al. The effect of inhaled budesonide and formoterol on bronchial remodeling and HRCT features in young asthmatics. Lung 2007 Mar; 185 (2): 89-96
31. Boobis AR. Comparative physiochemical and pharmacokinetic profiles of inhaled beclomethasone dipropionate and budesonide. Respir Med 1998; 92 Suppl. B: 2-6
32. McGavin JK, Goa KL, Jarvis B. Inhaled budesonide/formoterol combination. Drugs 2001; 61 (1): 71-8
33. Newman SP, Pitcairn GR, Hirst PH, et al. Scintigraphic comparison of budesonide deposition from two dry powder inhalers. Eur Respir J 2000 Jul; 16 (1): 178-83
34. Thorsson L, Edsbäcker S, Conradson T-B. Lung deposition of budesonide from Turbuhaler® is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J 1994; 7: 1839-44
35. Kaiser H, Aaronson D, Dockhorn R, et al. Dose-proportional pharmacokinetics of budesonide inhaled via Turbuhaler®. Br J Clin Pharmacol 1999 Sep; 48 (3): 309-16
36. Thorsson L, Edsbäcker S, Källén A, et al. Pharmacokinetics and systemic activity of fluticasone via Diskus® and pMDI, and of budesonide via Turbuhaler®. Br J Clin Pharmacol 2001; 52: 529-38
37. Bousquet J, Boulet LP, Peters MJ, et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/ fluticasone. Respir Med. Epub 2007 Oct 1
38. Kuna P, Peters MJ, Manjra AI, et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007 May; 61 (5): 725-36
39. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005 Jan 15; 171 (2): 129-36
40. Rabe KF, Atienza T, Magyar P, et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006 Aug 26; 368 (9537): 744-53
41. Rabe KF, Pizzichini E, Ställberg B, et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 2006 Feb; 129 (2): 246-56
42. Scicchitano R, Aalbers R, Ukena D, et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004 Sep; 20 (9): 1403-18
43. Lundborg M, Wille S, Bjermer L, et al. Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: an efficacy and cost-effectiveness study. Curr Med Res Opin 2006 May; 22 (5): 809-21
44. Sears R, Boulet LP, Laviolette M, et al. Budesonide/formoterol maintenance and reliever therapy for asthma compared to conventional best practice: a randomised real-life study [abstract no. E3601]. Eur Respir J 2006 Sep; 28 Suppl. 50: 613-4s
45. Vogelmeier C, D'Urzo A, Pauwels R, et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Resp J 2005 Nov; 26 (5): 819-28
46. Buhl R, Vogelmeier C. Budesonide/formoterol maintenance and reliever therapy: a new treatment approach for adult patients with asthma. Curr Med Res Opin 2007; 23 (8): 1867-78
47. Johansson G, Andreasson EB, Larsson PE, et al. Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics 2006; 24 (7): 695-708
48. Miller E, Sears MR, McIvor A, et al. Canadian economic evaluation of budesonide-formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Can Respir J 2007 Jul; 14 (5): 269-75
49. Price D, Wirén A, Kuna P. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allerfor gy 2007 Oct; 62 (10): 1189-98
50. Bousquet J, Miravitlles M, Wirén A. Budesonide/formoterol provides better efficacy at a lower or similar cost as compared to high-dose salmeterol/fluticasone treatment [abstract no. P1185]. Eur Respir J 2007 Sep; 30 Suppl. 51: 193s
51. Martinez FD. Safety of long-acting beta-agonists: an urgent need to clear the air. N Engl J Med 2005 Dec 22; 353 (25): 2637-9
52. FDA public health advisory: Serevent Diskus (salmeterol xinofoate inhalation powder), Advair Diskus (fluticasone propionate & salmeterol inhalation powder), Foradil Aerolizer (formoterol fumarate inhalation powder) [online]. Available from URL: http://www.fda.gov/cder/drug/advisory/laba.htm [Accessed 2007 Sep 24]
53. Martinez FD. Serious adverse events and death associated with treatment using long-acting β-agonists. Clin Rev Allergy Immunol 2006; 31 (2-3): 269-78
54. Symbicort® (budesonide/formoterol) Turbuhaler®, 160/4.5 micrograms/inhalation, inhalation powder: summary of product characteristics (Sweden) [online]. Available from URL: http://www.lakemedelsverket.se/upload/ SPC_PIL/Pdf/enhumspc [Accessed 2007 Aug 13]
55. Tattersfield AE, Postma DS, Barnes PJ, et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. Am J Respir Crit Care Med 1999 Aug; 160 (2): 594-9
56. Tattersfield AE, Löfdahl CG, Postma DS, et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet 2001 Jan 27; 357 (9252): 257-61
57. Barnes PJ. Using a combination inhaler (budesonide plus formoterol) as rescue therapy improves asthma control. BMJ 2007 Sep 8; 335 (7618): 513